Current Report Filing (8-k)
February 06 2023 - 4:16PM
Edgar (US Regulatory)
0001662382
false
--12-31
0001662382
2023-01-31
2023-01-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 31, 2023
BRAIN SCIENTIFIC INC.
(Exact name of registrant as specified in its charter)
Nevada |
|
000-56216 |
|
81-0876714 |
(State or other jurisdiction of
incorporation
or organization) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
6700 Professional Parkway
Lakewood Ranch, Florida 34240
(Address of principal executive offices)
(917) 388-1578
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
None |
|
None |
|
None |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On January 31, 2023, Brain Scientific Inc. (the
“Company”) filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of
Nevada (the “Amendment”) in order to effectuate a 1-for-85 reverse stock split of the Company’s issued and outstanding
shares of common stock (the “Reverse Split”). The Reverse Split was approved by the Financial Industry Regulatory Authority
(FINRA) and became effective in the market on February 3, 2023 (the “Effective Date”).
The above description of the Amendment does not
purport to be complete and is qualified in its entirety by reference to the Amendment, which is attached hereto as Exhibit 3.1 to this
Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 6, 2023 |
By: |
/s/ Hassan Kotob |
|
|
Hassan Kotob |
|
|
Chief Executive Officer |
2
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From Apr 2024 to May 2024
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From May 2023 to May 2024